<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01504997</url>
  </required_header>
  <id_info>
    <org_study_id>DaVinci_SCC</org_study_id>
    <secondary_id>UMIN000006910</secondary_id>
    <nct_id>NCT01504997</nct_id>
  </id_info>
  <brief_title>Phase II Study for Robot Assisted Distal Gastrectomy</brief_title>
  <acronym>RADGphaseII</acronym>
  <official_title>A Phase II Study of Robot Assisted Distal Gastrectomy With Nodal Dissection for Clinical Stage Ia Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shizuoka Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shizuoka Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to clarify safety of robot assisted distal gastrectomy with lymph
      node dissection in patients with stage Ia early gastric cancer.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Incidence of Post-operative Intra-abdominal Infectious Complications</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse Free Survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Completion Rate of Robot Assisted Surgery</measure>
    <time_frame>During the surgery, an expected average of 5 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Early Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Robot assisted distal gastrectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients who received robot assisted distal gastrectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Robot assisted distal gastrectomy (DaVinci)</intervention_name>
    <description>patients who received robot assisted distal gastrectomy</description>
    <arm_group_label>Robot assisted distal gastrectomy</arm_group_label>
    <other_name>DaVinci</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Biopsy specimen from the primary lesion shows adenocarcinoma

          2. Diagnosed as Stage IA early gastric cancer according to the preoperative
             esophagogastroduodenoscopy and computer tomography

          3. Endoscopic submucosal dissection is not indicated

          4. Tumor was located within lower two thirds of stomach

          5. Not having duodenal invasion

          6. Eastern clinical oncology group performance status is 0 or 1

          7. Body mass index is lower than 30

          8. No prior laparotomy

          9. No prior chemotherapy or radiation including those for other cancers

         10. Fulfil all following conditions WBC &gt; 3,000/mm3 Plt &gt; 100,000/mm3 AST &lt; 100 IU/L ALT &lt;
             100IU/L T.Bil &lt; 2.0 g/dl Cre &lt; 1.5mg/dl

        Exclusion Criteria:

          1. Having other active cancers

          2. Possibly pregnant, or breast feeding woman

          3. with psychiatric disorder

          4. Receiving steroids

          5. With Acute myocardial infarction in 6 months or with unstable angina

          6. With uncontrolled hypertension

          7. With uncontrolled diabetes mellitus

          8. With pulmonary disease which require continuous oxygen therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masanori Terashima, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Gastric Surgery, Shizuoka Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shizuoka Cancer Center</name>
      <address>
        <city>Shizuoka</city>
        <zip>411-0934</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 30, 2011</study_first_submitted>
  <study_first_submitted_qc>January 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2012</study_first_posted>
  <results_first_submitted>April 18, 2016</results_first_submitted>
  <results_first_submitted_qc>April 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 25, 2016</results_first_posted>
  <last_update_submitted>October 12, 2016</last_update_submitted>
  <last_update_submitted_qc>October 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shizuoka Cancer Center</investigator_affiliation>
    <investigator_full_name>Masanori Terashima</investigator_full_name>
    <investigator_title>Head of Gastric Surgery</investigator_title>
  </responsible_party>
  <keyword>DaVinci</keyword>
  <keyword>Robot assisted surgery</keyword>
  <keyword>Gastrectomy</keyword>
  <keyword>Safety</keyword>
  <keyword>Gastric Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 23 patients were recruited for the study, and the initial 5 cases were excluded from the primary analysis because some of the initial RAGs were performed by invited surgeons who had lots of experience. This exclusion was prespecified in the protocol. Therefore, only the remaining 18 patients were included in the analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Robot Assisted Distal Gastrectomy</title>
          <description>patients who received robot assisted distal gastrectomy
Robot assisted distal gastrectomy (DaVinci): patients who received robot assisted distal gastrectomy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Robot Assisted Distal Gastrectomy</title>
          <description>patients who received robot assisted distal gastrectomy
Robot assisted distal gastrectomy (DaVinci): patients who received robot assisted distal gastrectomy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.5" lower_limit="53" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Incidence of Post-operative Intra-abdominal Infectious Complications</title>
        <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Robot Assisted Distal Gastrectomy</title>
            <description>patients who received robot assisted distal gastrectomy
Robot assisted distal gastrectomy (DaVinci): patients who received robot assisted distal gastrectomy</description>
          </group>
        </group_list>
        <measure>
          <title>The Incidence of Post-operative Intra-abdominal Infectious Complications</title>
          <units>participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relapse Free Survival</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Completion Rate of Robot Assisted Surgery</title>
        <time_frame>During the surgery, an expected average of 5 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Events</title>
        <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 10 days</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Robot Assisted Distal Gastrectomy</title>
          <description>patients who received robot assisted distal gastrectomy
Robot assisted distal gastrectomy (DaVinci): patients who received robot assisted distal gastrectomy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Doctor Masanori Tokunaga</name_or_title>
      <organization>Shizuoka Cancer Center</organization>
      <phone>81-55098908777</phone>
      <email>m.tokunaga@scchr.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

